Physician profile
Lananh Ly
NPI 1710418272
$3,041.14
in general payments reported to CMS, 2019-2025
24 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,589 · 2022: $580 · 2023: $405 · 2024: $183 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $799.82 | 2021-2025 | |
| Novo Nordisk INC | $468.37 | 2021-2023 | Norditropin |
| Lilly USA, LLC | $288.94 | 2021-2022 | |
| Dexcom, INC. | $189.72 | 2021-2022 | |
| Abbott Laboratories | $182.67 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $161.09 | 2021-2022 | |
| Mannkind Corporation | $145.57 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.30 | 2021-2022 | |
| Zealand Pharma US, INC. | $103.09 | 2021-2022 | |
| Medtronic, INC. | $87.82 | 2021 | |
| Insulet Corporation | $67.98 | 2021-2022 | |
| Merz North America, INC. | $67.00 | 2025 | |
| Xeris Pharmaceuticals, INC. | $55.55 | 2021-2022 | |
| Ibsa Pharma INC. | $52.43 | 2021 | |
| Revance Therapeutics, INC. | $47.43 | 2024 | Daxxify |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $43.40 | 2021 | |
| Amgen INC. | $36.93 | 2021-2022 | |
| Allergan, INC. | $21.33 | 2022 | |
| Lifescan, INC. | $21.08 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.27 | 2021 | |
| Vivus LLC | $20.25 | 2021 | |
| Merck Sharp & Dohme LLC | $19.16 | 2021 | |
| Grt US Holding, INC. | $18.58 | 2022 | |
| Endo Pharmaceuticals INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lananh Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.